A Case Report: Insulinoma in a Military Pilot Detected by 68Ga-Dotatate PET/CT
Authors:
Open Access
- 3 July 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Military Medicine
- Vol. 185 (9-10) , e1887-e1890
Abstract
A 37-year-old active duty male Air Force instructor pilot, with no prior medical history, was found unresponsive at his home after awakening with symptoms of altered mental status when the Emergency Medical Service (EMS) was called. The patient was found to be hypoglycemic with a glucose of 37 mg/dL. The patient recovered after administration of a dextrose bolus. Further investigation revealed that over the last several years, the patient exhibited symptoms of lightheadedness and tremors if fasted greater than 3 hours. Further clinical workup strongly suggested the presence of a neuroendocrine tumor. Initial imaging studies to include a multiphasic dedicated pancreatic computed tomography (CT) scan did not demonstrate a pancreatic lesion. However, the utilization of an innovative new nuclear medicine imaging modality, a 68Ga-Dotatate PET/CT, clearly demonstrated a 19 × 16 mm lesion of the distal pancreatic tail, which guided surgical resection. He underwent a robotic-assisted laparoscopic distal pancreatectomy, pathologically characterized as an insulinoma. The patient’s symptoms immediately resolved with no recurrence over the next 6 months. The pilot was granted a waiver, returning him to his flying duties. The 68Ga-Dotatate PET/CT enabled the identification of an otherwise occult pancreatic neuroendocrine tumor ultimately leading to this patient’s definitive cure and the salvage of this military asset’s aviation career.Keywords
This publication has 10 references indexed in Scilit:
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesJAMA Oncology, 2017
- Role of 68Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine TumorsJournal of Nuclear Medicine, 2016
- 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-Octreotide SPECT/CT, and Whole-Body MR Imaging in Detection of Neuroendocrine Tumors: A Prospective TrialJournal of Nuclear Medicine, 2014
- The Role of 68Ga-DOTATATE PET/CT in Suspected Neuroendocrine TumorsJournal of Nuclear Medicine, 2012
- High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumoursJournal of Medical Imaging and Radiation Oncology, 2012
- NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine TumorPancreas, 2010
- The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide ScintigraphyJournal of Nuclear Medicine, 2010
- Secular Trends in the Presentation and Management of Functioning Insulinoma at the Mayo Clinic, 1987–2007The Journal of Clinical Endocrinology & Metabolism, 2009
- Functioning Insulinoma—Incidence, Recurrence, and Long-Term Survival of Patients: A 60-Year StudyMayo Clinic Proceedings, 1991